PPARA and hyperlipidemia: PPAR agonists, used as drugs for hyperlipidemia and type2 diabetes, show some encouraging results in PBC treatment (Jones et al., 2017; Corpechot et al., 2018) and, thus, are considered potential therapeutic targets.